D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
WALTHAM, MA—In a recent transaction, Xiao Ting, a director at Zenas BioPharma, Inc. (NASDAQ:ZBIO), purchased 10,000 shares of the company’s common stock. The shares were acquired on February 7, 2025, at a weighted average price of $7.76 per share, resulting in a total transaction value of $77,600. The stock, currently trading at $10.40, has appreciated significantly since the director’s purchase, reflecting the company’s strong momentum. According to InvestingPro data, ZBIO maintains a healthy balance sheet with more cash than debt, while analysts have set price targets ranging from $18 to $45.
The purchase was made in several transactions, with prices ranging from $7.64 to $7.78 per share. Following this acquisition, Ting holds a total of 10,000 shares in direct ownership. This filing amends a previous report that inaccurately stated the post-transaction share count. The $419 million market cap company has shown impressive recent performance, with a 22% gain year-to-date. Want deeper insights into insider trading patterns and 10 additional exclusive ProTips? Check out InvestingPro.
In other recent news, Zenas BioPharma has announced significant changes to its leadership team as it continues to advance its flagship product, obexelimab, through critical clinical trials. The company appointed Haley Laken, Ph.D., as its new Chief Scientific Officer. Dr. Laken brings over two decades of experience in drug development and translational research, previously holding leadership positions at companies such as Tabby Therapeutics and Pfizer (NYSE:PFE). Additionally, Zenas BioPharma has named Lisa von Moltke, M.D., as the new Head of Research and Development and Chief Medical (TASE:BLWV) Officer. Dr. von Moltke has a wealth of experience in drug development for autoimmune diseases and has held significant roles at Seres Therapeutics (NASDAQ:MCRB) and Sanofi/Genzyme Corporation. Both Dr. Laken and Dr. von Moltke will focus on advancing obexelimab, a bifunctional monoclonal antibody targeting B cells, through Phase 2 and Phase 3 trials for autoimmune diseases. The company emphasizes the potential of obexelimab’s unique mechanism of action, which inhibits B cells without depleting them, as a differentiator in the treatment of chronic autoimmune diseases. Zenas BioPharma’s strategic focus remains on developing therapies that offer superior clinical benefits to patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.